Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2008-09-16
2011-11-29
Ha, Julie (Department: 1654)
Chemistry: molecular biology and microbiology
Vector, per se
C435S006120, C435S325000, C435S348000, C424S189100, C424S228100
Reexamination Certificate
active
08067228
ABSTRACT:
Peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N° 1, a peptide B having at least the amino acid sequence of SEQ ID N° 45, a peptide C having at least the amino acid sequence of SEQ ID N° 127, and a peptide D having at least the amino acid sequence of SEQ ID N° 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.
REFERENCES:
patent: 5106726 (1992-04-01), Wang
patent: 5436126 (1995-07-01), Wang
patent: 5582968 (1996-12-01), Wang et al.
patent: 5639594 (1997-06-01), Wang et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5712087 (1998-01-01), Houghton et al.
patent: 5736321 (1998-04-01), Hosein et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 6150087 (2000-11-01), Chien
patent: 6312889 (2001-11-01), Houghton et al.
patent: 6346375 (2002-02-01), Chien
patent: 6534482 (2003-03-01), Fikes et al.
patent: 6562346 (2003-05-01), Paliard et al.
patent: 6635257 (2003-10-01), Depla et al.
patent: 7393831 (2008-07-01), Fournillier et al.
patent: 2002/0115061 (2002-08-01), Chisari et al.
patent: 2003/0095980 (2003-05-01), Maertens et al.
patent: 2003/0118603 (2003-06-01), Maertens et al.
patent: 2003/0194747 (2003-10-01), Georges et al.
patent: 2003/0202987 (2003-10-01), Depla et al.
patent: 2003/0203869 (2003-10-01), Fikes et al.
patent: 2007/0020285 (2007-01-01), Fournillier et al.
patent: 2007/0072176 (2007-03-01), Inchauspe et al.
patent: 0 388 232 (1990-09-01), None
patent: 0 450 931 (1991-04-01), None
patent: 0 468 527 (1991-07-01), None
patent: 1506225 (2006-07-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 99/58658 (1999-11-01), None
patent: WO 99/67285 (1999-12-01), None
patent: WO 01/21189 (2001-03-01), None
patent: WO 01/30812 (2001-05-01), None
patent: WO 01/90197 (2001-11-01), None
patent: WO 01/92311 (2001-12-01), None
patent: WO 02/070006 (2002-09-01), None
patent: WO 03/097677 (2003-11-01), None
Eck SL and Wilson JM, “Gene-Based Therapy,” Goodman & Gilman's The Pharmaological basis of Therapeutics, McGraw-Hill, New Yor, NY. 1996, 77-101.
Verma IM and Somia N, “Gene therapy-promises, problems and prospects,” Nature, 1997, 389: 239-242.
Pfeifer A and Verma IM, “Gene Therapy: Promises and Problems,” Annual Review of Genomics and Human Genetics, 2001, 2:177-211).
Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K, “Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis,” Proc. Natl. Acad. Sci. USA, 1990, 87: 9524-9528.
U.S. Appl. No. 12/132,321, filed Jun. 3, 2008, Fournillier et al.
Abrams et al., “Generation of Stable CD4 and CD8 T-cell Lines from Patients Immunized with ras Oncogene-Derived Peptides Reflecting Codon 12 Mutations,”Cell. Immunol.182:137-151, 1997.
Battegay et al., “Patients with Chronic Hepatitis C Have Circulating Cytotoxic T-cells Which Recognize Hepatitis C Virus-Encoded Peptides Binding to HLA-A2.1 Molecules,”J. Virol.69:2462-2470, 1995.
Brinster et al., “Different Hepatitis C Virus Nonstructural Protein 3 (NS3)-DNA-Expressing Vaccines Induce in HLA-A2.1 Transgenic Mice Stable Cytotoxic T Lymphocytes that Target One Major Epitope,”Hepatology34:1206-1217, 2001.
Chang et al., “Identification of HLA-A3 and -B7-Restricted CTL Response to Hepatitis C Virus in Patients with Acute and Chronic Hepatitis C,”J. Immunol.162:1156-1164, 1999.
Definition of “epitope,” inImmunobiology,4th Edition, p. 600, 1999.
Diepolder et al., “Immunodominant CD4+T-cell Epitope Within Nonstructural Protein 3 in Acute Hepatitis C Virus Infection,”J. Virol.71:6011-6019, 1997.
Fournillier et al., “Primary and Memory T Cell Responses Induced by Hepatitis C Virus Multiepitope Long Peptides,”Vaccine24:3153-3164, 2006.
Fytili et al., “Cross-Genotype-Reactivity of the Immunodominant HCV CD8 T-cell Epitope NS3-1073,”Vaccine,online publication, Jun. 2008.
Heile et al., “Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: An Endoplasmic Reticulum-Retained Recombinant Protein is Superior to Secreted Recombinant Protein and DNA-based Vaccine Candidates,”J. Virol.74:6885-6892, 2000.
Himoudi et al., “Comparative Vaccine Studies in HLA-A2.1-Transgenic Mice Reveal a Clustered Organization of Epitopes Presented in Hepatitis C Virus Natural Infection,”J. Virol.76:12735-12746, 2002.
Kozeil et al., “Hepatitis C Virus (HCV)-Specific Cytotoxic T Lymphocytes Recognize Epitopes in the Core and Envelope Proteins of HCV,”J. Virol.367:7522-7532, 1993.
Lamonaca et al., “Conserved Hepatitis C Virus Sequences are Highly Immunogenic for CD4+T Cells: Implications for Vaccine Development,”Hepatology30:1088-1098, 1999.
Lechner et al., “Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus,”J. Exp. Med.191:1499-1512, 2000.
Leroux-Roels, “Development of Prophylactic and Therapeutic Vaccines Against Hepatitis C Virus,”Expert Rev. Vaccines4:351-371, 2005.
Manns et al., “The Way Forward in HCV Treatment- Finding the Right Path,”Nature Rev. Drug Discov.6:991-1000, 2007.
Martin et al., “Genetic Immunization and Comprehensive Screening Approaches in HLA-A2 Transgenic Mice Lead to the Identification of Three Novel Epitopes in Hepatitis C Virus NS3 Antigen,”J. Med. Virol.74:397-405, 2004.
Martin et al., “A Vector-Based Minigene Vaccine Approach Results in Strong Induction of T-cell Responses Specific of Hepatitis C Virus,”Vaccine26:2471-2481, 2008.
Pancholi et al., “DNA Immunization with Hepatitis C Virus (HCV) Polycistronic Genes or Immunization by HCV DNA Priming-Recombinant Canarypox Virus Boosting Induces Immune Responses and Protection from Recombinant HCV-Vaccinia Virus Infection in HLA-A2.1-Transgenic Mice,”J. Virol.77:382-390, 2003. Abstract only.
Pascolo et al., “HLA-A2.1-Restricted Education and Cytolytic Activity of CD8+T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Dbβ2m Double Knockout Mice,”J. Exp. Med.185:2043-2051, 1997.
Puig et al., “CD4+Immune Escape and Subsequent T-cell Failure Following Chimpanzee Immunization Against Hepatitis C Virus,”Hepatology44:736-745, 2006.
Qiao et al., “Hepatitis C Virus-Like Particles Combined with Novel Adjuvant Systems Enhance Virus-Specific Responses,”Hepatology37:52-59, 2003. Abstract only.
Racanelli et al., “Dendritic Cells Transfected with Cytopathic Self-Replicating RNA Induce Crossprinting of CD8+T Cells and Antiviral Immunity,”Immunity20:47-58, 2004. Abstract only.
Rollier et al., “Control of Heterologous Hepatitis C Virus Infection in Chimpanzees is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response,”J. Virol.78:187-196, 2004.
Rudikoff et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity,”Proc. Natl. Acad. Sci. U.S.A.79:1979-1983, 1982.
Shirai et al., “An Epitope in Hepatitis C Virus Core Region Recognized by Cytotoxic T cells in Mice and Humans,”J. Virol.68:3334-3342, 1994.
Simon et al., “DNA Vaccination Protects Mice Against Challenge withListeria monocytogenesExpressing the Hepatitis C Virus NS3 Protein,”Infect. Immun.71:6372-6380, 2003.
Spaulding et al., “Analysis of Murine CD8(+) T-cell Clones Specific for the Dengue Virus NS3 Protein: Flavivirus Cross-Reactivity and Influence of Infecting Serotype,”J. Virol.73:398-403, 1999.
Sutter et al., “Nonreplicating Vaccinia Vector Efficiently Expresses Recombinant Genes,”Proc. Natl. Acad. Sci. U.S.A.8
Fournillier Anne
Himoudi Nourredine
Inchauspe Genevieve
Clark & Elbing LLP
Ha Julie
INSERM (Institut National de la Sante et de la Recherche Medical
Transgene SA
LandOfFree
Nucleic acid compositions and their use against the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid compositions and their use against the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid compositions and their use against the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4259471